Determinants of survival after liver resection for metastatic colorectal carcinoma

Journal of B.U.ON.

Volumn 20, Issue 1, 2015, Pages 68-77

  Parau, Angela ^a   Todor, Nicolae ^b   Vlad, Liviu ^c  

^a Department of Nuclear Medicine   (Romania)

^b THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^c IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Colorectal cancer; Hepatic metastases; Liver resection; Prognostic factors

Indexed keywords

BEVACIZUMAB; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; FLUOROPYRIMIDINE; IRINOTECAN; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; COLORECTAL LIVER METASTASIS; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; HUMAN; LIVER RESECTION; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; METASTASIS RESECTION; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PREOPERATIVE PERIOD; REOPERATION; SURVIVAL RATE; SURVIVAL TIME; TUMOR DIFFERENTIATION; ADVERSE EFFECTS; AGED; CANCER STAGING; CARCINOMA; COLORECTAL TUMOR; DISEASE COURSE; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; SECONDARY; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HEPATECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; REOPERATION; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84928700429     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Kopetz S, Chang GJ, Overman MJ et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009;27:3677-3683.
2. Giacchetti S, Perpoint B, Zidani R et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first- line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136.
3. De-Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first- line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
4. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-237.
5. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905.
6. Hurwitz H, Fehrenbacher L, Novotny W et al. Bev- Acizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335.
7. Giantonio BJ, Catalano PJ, Meropol NJ et al. Beva- cizumab in combination with oxaliplatin, fluorouracil, and leucovorin (F0LF0X4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007:25:1539.
8. Cunningham D, Humblet Y, Siena S et al. Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer. N Engl J Med 2004;351:337-345.
9. Van-Cutsem E, Lang I, D'haens G et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 2008;26 (SuppI), abstr no. 2.
10. Van-Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658.
11. Grothey A, Van Cutsem E, Sobrero A et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:303-312.
12. Perkins SL, Cole SW. Ziv-aflibercept (Zaltrap) for the treatment of metastatic colorectal cancer. Ann Phar- macother 2014;48:93-98.
13. Rosen CB, Nagorney DM, Taswell HF et al. Perioper-ative blood transfusion and determinants of survival after liver resection for metastatic colorectal carcinoma. Ann Surg 1992;216:493-504.
14. Scheele J, Rudroff C, Altendorf-Hofmann A. Resection of colorectal liver metastases revisited. J Gastrointest Surg 1997;1:408-422.
15. Nordlinger B, Guiguet M, Vaillant JC et al. Surgical resection of colorectal carcinoma metastases to the liver: a prognostic scoring system to improve case selection, based on 1568 patients. Association Fran- caise de Chirurgie. Cancer 1996;77:1254-1262.
16. American Joint Committee on Cancer. AJCC Cancer Staging Manual (7th Edn). Philadelphia: Lippin- cott-Raven, 2010, pp 66-69.
17. Bismuth H. Surgical anatomy and anatomical surgery of the liver. World J Surg 1982;6:3-9.
18. Terminology Committee of the International Hepa- to-Pancreato-Biliary Association. Brisbane 2000 Terminology of Liver Anatomy & Resections. Hepatobiliary Pancreat Surg 2000;2:333-339.
19. Rosner B. Fundamentals of Biostatistics (7th Edn). Duxbury Press; 2010.
20. Fong Y, Fortner J, Sun RL et al. Clinical score for pre-dicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230:309-321.
21. Jaeck D, Bachellier P, Guiguet M et al. Long-term survival following resection of colorectal hepatic metastases. Br J Surg 1997;84:977-980.
22. Jamison RL, Donohue JH, Nagorney DM et al. Hepatic resection for metastatic colorectal cancer: results in cure for some patients. Arch Surg 1997;132:505-510.
23. Faivre J, Manfredi S, Bouvier AM. Epidemiology of colorectal cancer liver metastases. Bull Acad Natl Med 2003;187:815-822.
24. Scheele J, Altendorf-Hofmann A. Resection of colorectal liver metastases. Langenbecks Arch Surg 1999;384:313-327.
25. Ueno H, Mochizuki H, Hatsuse K et al. Indicators for treatment strategies of colorectal liver metastases. Ann Surg 2000;231:59-66.
26. Lise M, Bacchetti S, Da-Pian P et al. Patterns of re-currence after resection of colorectal liver metastases: prediction by models of outcome analysis. World J Surg 2001;25:638-644.
27. Schindl M, Wigmore SJ, Currie EJ et al. Prognostic scoring in colorectal cancer liver metastases:development and validation. Arch Surg 2005;140:183-189.
28. Rees M, Tekkis PP, Welsh FK, O'Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 2008;247:125-135.
29. Fowler WC, Eisenberg BL, Hoffman JP. Hepatic resec-tion following systemic chemotherapy for metastatic colorectal carcinoma. J Surg Oncol 1992;51:122-125.
30. Giacchetti S, Itzhaki M, Gruia G et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-flourouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999;10:663-669.
31. Adam R, Wicherts DA, de-Haas RJ et al. Patients with initially unresectable colo-rectal liver metastases: is there a possibility of cure? J Clin Oncol 2009;27:1829-1835.
32. Folprecht G, Grothey A, Alberts S, Raab HR, Kohne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005;16:1311-1319.
33. Douillard JY, Cunnigham D, Roth AD et al. Irinote- can combined with fluorouracil compared with fluo- rouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355(9209):1041-1047.
34. Ychou M, Viret F, Kramar A et al. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharmacol 2008;62:195-201.
35. Bokemeyer C, Bondarenko I, Hartmann JTet al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOL- FOX with or without cetuximab: the OPUS experience. J Clin Oncol 2008;26:4000 (abstr).
36. Maughan T, Adams RA, Smith CG et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy (CT) for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011;377:2103-2114.
37. Van-Cutsem E, Kohne CH, Lang I et al. Cetuximab plus irinotecan, fluorouracil and leucovorin as first- line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011-2019.
38. Van-Cutsem E, Bokemeyer C, Haeger S, Sartorius U, Rougier P, Kohne C. Outcome according to metastatic site in patients with KRAS wild-type tumors: Analysis from CRYSTAL and OPUS studies. J Clin Oncol 2011;29 (4 Suppl):472 (abstr).
39. Folprecht G, Gruenberger T, Bechstein WO et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010;11:38-47.
40. Douillard JY, Sienna S, Cassidy J et al. Randomised phase III trial of panitumumab with infusional fuoro- uracil, leucovorin and oxaliplatin (F0LF0X4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28:4697-4705.
41. Hurwitz H, Fehrenbacher L, Novotny W et al. Bev- Acizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
42. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23;3706-3712.
43. Portier G, Elias D, Bouche O et al. Multicenter ran-domized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006;24:4976-4982.
44. Langer B, Bleiberg H, Labianca R et al. Fluorouracil (FU) plus 1-leucovorin (1-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial. Proc Am Soc Clin Oncol 2002;21:592 (abstr).
45. Mitry E, Fields AL, Bleiberg H et al. Adjuvant chemo-therapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008;26:4906-4911.
46. Nordlinger B, Sorbye H, Glimelius B et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008;371:1007-1016.
47. Wieser M, Sauerland S, Arnold D, Schmigel W, Re- inacher-Schick A. Peri-operative chemotherapy for the treatment of resectable liver metastases from colorectal cancer: a systematic review and me-ta-analysis from randomized trials. BMC Cancer 2010:10:39.